Unknown

Dataset Information

0

Discovery of marinopyrrole A (maritoclax) as a selective Mcl-1 antagonist that overcomes ABT-737 resistance by binding to and targeting Mcl-1 for proteasomal degradation.


ABSTRACT: The anti-apoptotic Bcl-2 family of proteins, including Bcl-2, Bcl-X(L) and Mcl-1, are well-validated drug targets for cancer treatment. Several small molecules have been designed to interfere with Bcl-2 and its fellow pro-survival family members. While ABT-737 and its orally active analog ABT-263 are the most potent and specific inhibitors to date that bind Bcl-2 and Bcl-X(L) with high affinity but have a much lower affinity for Mcl-1, they are not very effective as single agents in certain cancer types because of elevated levels of Mcl-1. Accordingly, compounds that specifically target Mcl-1 may overcome this resistance. In this study, we identified and characterized the natural product marinopyrrole A as a novel Mcl-1-specific inhibitor and named it maritoclax. We found that maritoclax binds to Mcl-1, but not Bcl-X(L), and is able to disrupt the interaction between Bim and Mcl-1. Moreover, maritoclax induces Mcl-1 degradation via the proteasome system, which is associated with the pro-apoptotic activity of maritoclax. Importantly, maritoclax selectively kills Mcl-1-dependent, but not Bcl-2- or Bcl-X(L)-dependent, leukemia cells and markedly enhances the efficacy of ABT-737 against hematologic malignancies, including K562, Raji, and multidrug-resistant HL60/VCR, by ?60- to 2000-fold at 1-2 ?M. Taken together, these results suggest that maritoclax represents a new class of Mcl-1 inhibitors, which antagonizes Mcl-1 and overcomes ABT-737 resistance by targeting Mcl-1 for degradation.

SUBMITTER: Doi K 

PROVIDER: S-EPMC3323047 | biostudies-literature | 2012 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Discovery of marinopyrrole A (maritoclax) as a selective Mcl-1 antagonist that overcomes ABT-737 resistance by binding to and targeting Mcl-1 for proteasomal degradation.

Doi Kenichiro K   Li Rongshi R   Sung Shen-Shu SS   Wu Hongwei H   Liu Yan Y   Manieri Wanda W   Krishnegowda Gowdahalli G   Awwad Andy A   Dewey Alden A   Liu Xin X   Amin Shantu S   Cheng Chunwei C   Qin Yong Y   Schonbrunn Ernst E   Daughdrill Gary G   Loughran Thomas P TP   Sebti Said S   Wang Hong-Gang HG  

The Journal of biological chemistry 20120206 13


The anti-apoptotic Bcl-2 family of proteins, including Bcl-2, Bcl-X(L) and Mcl-1, are well-validated drug targets for cancer treatment. Several small molecules have been designed to interfere with Bcl-2 and its fellow pro-survival family members. While ABT-737 and its orally active analog ABT-263 are the most potent and specific inhibitors to date that bind Bcl-2 and Bcl-X(L) with high affinity but have a much lower affinity for Mcl-1, they are not very effective as single agents in certain canc  ...[more]

Similar Datasets

| S-EPMC6781566 | biostudies-literature
| S-EPMC3817219 | biostudies-literature
| S-EPMC4260730 | biostudies-literature
| S-EPMC3591608 | biostudies-literature
| S-EPMC2953559 | biostudies-literature
| S-EPMC3434657 | biostudies-literature
| S-EPMC4937737 | biostudies-literature
| S-EPMC3040859 | biostudies-literature
| S-EPMC2582212 | biostudies-literature
| S-EPMC2786688 | biostudies-literature